Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia
Yue Zhong, Runze Qiu, Shan‐Liang Sun, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 21, pp. 12403-12428
Closed Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Overcoming cancer therapy resistance: From drug innovation to therapeutics
Jinrui Wei, Meng‐Yi Lu, Tian‐Hua Wei, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101229-101229
Closed Access | Times Cited: 2
FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance
Zhijie Wang, Jiongheng Cai, Jie Cheng, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 6, pp. 2878-2900
Closed Access | Times Cited: 64
Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy
Jing Ye, Junhao Wu, Bo Liu
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 3, pp. 188866-188866
Closed Access | Times Cited: 27
Targeted Therapy Development in Acute Myeloid Leukemia
Tulasigeri M. Totiger, Anirban Ghoshal, Jenna Zabroski, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 641-641
Open Access | Times Cited: 25
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations
Zixuan Wang, Qingqing Li, Jiao Cai, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 4346-4375
Closed Access | Times Cited: 8
An update of new small-molecule anticancer drugs approved from 2015 to 2020
Xiaoxia Liang, Pan Wu, Qian Yang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 220, pp. 113473-113473
Closed Access | Times Cited: 41
Heterocyclic Compounds as Synthetic Tyrosinase Inhibitors: Recent Advances
Serena Vittorio, Christian Dank, Laura Ielo
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 9097-9097
Open Access | Times Cited: 19
Rational discovery of dual FLT3/HDAC inhibitors as a potential AML therapy
Zhijie Wang, Donglin Wu, Xiaofei Zhao, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115759-115759
Closed Access | Times Cited: 12
Synthesis and Anti-acute Myeloid Leukemia Activity of Cyclopropane-1,1-diamide Derivatives Containing Imidazo[1,2-a]pyridine
L. Eduardo Wu, Jiangdong Li, Zhonghua Shi, et al.
Chinese Journal of Organic Chemistry (2025) Vol. 45, Iss. 1, pp. 286-286
Closed Access
Metabolite Profiling of Danatinib in Mice Using Ultra‐High‐Performance Liquid Chromatography/Tandem Mass Spectrometry In Vitro and In Vivo
Meng‐Yuan Zhang, Yuan‐Wei Zhang, Shengnan Yu, et al.
Biomedical Chromatography (2025) Vol. 39, Iss. 3
Closed Access
Design, Synthesis, and Biological Evaluation of Novel Fms-Like Tyrosine Kinase 3/VEGFR2/Histone Deacetylase Inhibitors for the Treatment of Acute Myeloid Leukemia
Hua Tian, Yichen Liu, Songwen Lin, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)pyridine derivatives as novel FLT3-ITD inhibitors
Shiqi Wu, Pengjuan Zhao, Youli Hou, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117492-117492
Closed Access
Discovery of cmpd D6 (FH-001) as a effiency enhancement and myelosuppression degradation small-molecule Fms-like Tyrosine Kinase 3 Inhibitor for the treatment of FLT3-ITD Positive Acute Myeloid Leukemia
Yanan Qi, Xinyi Zhu, Jingjing Han, et al.
European Journal of Pharmacology (2025), pp. 177541-177541
Open Access
Identification of Thieno[3,2-d]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3
Hanna Cho, Injae Shin, Hojong Yoon, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 16, pp. 11934-11957
Closed Access | Times Cited: 26
Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia
Garrett M. Dancik, Ioannis F. Voutsas, Spiros Vlahopoulos
Molecular Biology Reports (2022) Vol. 49, Iss. 4, pp. 3321-3331
Open Access | Times Cited: 17
A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia
Ahmad Nasimian, Lina Al Ashiri, Mehreen Ahmed, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3830-3830
Open Access | Times Cited: 10
Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy
Bahareh Farasati Far, Dorsa Rabie, Parisa Hemati, et al.
Livers (2023) Vol. 3, Iss. 1, pp. 121-160
Open Access | Times Cited: 9
Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations
Zhijie Wang, Jiongheng Cai, Jiwei Ren, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 19, pp. 14664-14701
Closed Access | Times Cited: 23
Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach
Shih‐Chung Yen, Liang‐Chieh Chen, Han‐Li Huang, et al.
Bioorganic Chemistry (2022) Vol. 121, pp. 105675-105675
Open Access | Times Cited: 13
Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment
Chenchen Ma, Siyuan Cui, Ruirong Xu
Current Medicinal Chemistry (2024) Vol. 31, Iss. 29, pp. 4657-4686
Closed Access | Times Cited: 2
Discovery of FLT3-targeting PROTACs with potent antiproliferative activity against acute myeloid leukemia cells harboring FLT3 mutations
Zhijie Wang, Xun Lu, Canlin Liu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116237-116237
Closed Access | Times Cited: 2
Inhibition of FLT3-ITD Kinase in Acute Myeloid Leukemia by New Imidazo[1,2-b]pyridazine Derivatives Identified by Scaffold Hopping
Petra Břehová, Eva Řezníčková, Kryštof Škach, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 11133-11157
Open Access | Times Cited: 6
Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations
Tian‐Hua Wei, Zixuan Wang, Meng‐Yi Lu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
3H-Pyrazolo[4,3-f]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo
Neetu Dayal, Eva Řezníčková, Delmis E. Hernandez, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 10981-10996
Closed Access | Times Cited: 15
Aldehyde Dehydrogenase Enzyme Functions in Acute Leukemia Stem Cells
Garrett M. Dancik, Ioannis F. Voutsas, Spiros Vlahopoulos
Frontiers in Bioscience-Scholar (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top